News
Chr. Hansen reports that a new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness.
In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.
Flu-like sickness can take its toll on workforce productivity, health care systems and families with young children, the company notes, and is estimated to have an annual burden on the US economy of $11.2 billion .
According to Chr. Hansen, data from numerous studies already shows a positive correlation between taking certain probiotics and reducing the number of incidents, duration and severity of flu-like sickness. This new study builds upon existing data, to assess the potential health economic impact of probiotics in the US primary care setting. The findings show the significant savings potential taking probiotics can have by reducing the number of sick days, visits to the doctor and prescriptions.
Flu-like sickness is a wide-ranging category including a fever of at least 100°F (37.8°C) and a cough or sore throat. On average over the last five years, there have been 33 million symptomatic cases in the US each year.
“Probiotics are already well established in the healthcare industry, and numerous studies have highlighted the therapeutic potential of specific probiotic strains in helping to maintain a healthy immune system and supporting the defense against harmful bacteria. In addition to the health benefits to an individual, this study demonstrates that taking probiotics also contributes to reducing costs to society and reducing the use of antibiotics. We believe that the impact of probiotics on healthcare will continue to grow in the years to come as we continue to unlock the potential of good bacteria,” said Andrew Scorey, senior vice president, Chr. Hansen Human Health.
Chr. Hansen points out that, according to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security and development today, and it is expected to exceed cancer as the main cause of death by 2050. It is estimated that more than one in three of the antibiotics prescribed to treat flu-like sickness in the US are redundant.
The new study reveals that in the US, some 2.2 million antibiotic courses could be avoided each year if the population takes probiotics.
“We already know that the overuse of antibiotics can cause bacteria to become resistant, meaning current treatments will no longer work. This study provides further evidence of how probiotics and ‘good bacteria’ can respond to some of the world’s biggest challenges,” said Scorey.
The results of the study are published in the journal Frontiers in Pharmacology and were authored and reviewed by independent industry and academic experts. Chr. Hansen sponsored the development of a new simulation model used in the study. The publication title is: Probiotics reduce healthcare cost and societal impact of flu-like respiratory tract infections in the USA: An economic modeling study.
The underlying data used in the study came from two independent reviews: York Health Economics Consortium (YHEC) and Cochrane. The clinical trials in these reviews used 22 probiotic strains, including Chr. Hansen’s Lactobacillus rhamnosus and Bifidobacterium animalis.
“This study builds on independent clinical trials and translates the clinical findings into cost and impact on primary health care. The results present a very strong case for probiotics. At Chr. Hansen, we will continue to build on these findings looking closely into how specific strains can support this health area. As a result of this study, we now have a new simulation model that will provide us with new ways to work with data in future studies,” said Adam Baker, senior manager, Human Health Development at Chr. Hansen.
Chr. Hansen owns some of the world’s best documented probiotic strains. The large number of scientific publications and clinical studies on these strains indicate that they may have beneficial effects on the immune functions.
24 Nov 2025
OXO’s entry into bone broth has turned the spotlight on this small but high-performance category – and there is still scope for growth, especially in the area of GLP-1 support.
Read more
19 Nov 2025
Five years ago, it was a struggle to find matcha outside of Japan. Now it seems to be popping up everywhere, from coffee shops to supermarket shelves.
Read more
18 Nov 2025
Gen Z and millennial consumers’ preferences for transparency, functionality, and purpose are “redefining the very nature of consumption itself”, says SPINS.
Read more
17 Nov 2025
Trend forecasters expect food and drink to move more fluidly across occasions, functions, and formats as consumers seek versatility, novelty, and convenience.
Read more
13 Nov 2025
Divi’s Nutraceuticals offers a large portfolio of innovative, high-quality ingredients for foods, beverages, and supplements, with bespoke solutions and expert support for product success.
Read more
13 Nov 2025
Mill Powder Tech's smart control systems harness real-time data to help the food and biotech sectors achieve zero downtime and smarter output, alongside rigorous GMP standards and ambitious ESG goals.
Read more
13 Nov 2025
Paradise Fruits Solutions and Paradise Fruits Health will showcase their combined expertise in delivering innovative, fruit-based solutions to the food and beverage industry at the upcoming Fi Europe trade show (2-4 December 2025, Paris).
Read more
13 Nov 2025
Danone is betting on a food industry “tipping point” that will bloat the market for healthy products, particularly those related to gut health.
Read more
6 Nov 2025
Dairygold Co-operative Society, The Carbery Group, and Ornua Co-operative: Meet with sustainable producers of Irish dairy ingredients at Food ingredients Europe 2025, Hall 7.2 Stand M18.
Read more
5 Nov 2025
Some popular protein bars contain more fat, carbs, and/or sugars than claimed on their labels, independent nutrition testing reveals.
Read more